Arcadia Biosciences, Inc.

For the period ended Mar 31, 2026. Filed May 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

RKDA$0.17-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share data)

	March 31, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$954	$259
Short-term investments	2,766	4,304
Accounts receivable and other receivables, net of allowance for credit loss of $559 as of March 31, 2026 and December 31, 2025	425	425
Inventories	840	1,212
Prepaid expenses and other current assets	184	156
Total current assets	5,169	6,356
Property and equipment, net	—	8
Intangible assets, net	39	39
Other noncurrent assets	115	143
Total assets	$5,323	$6,546
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$1,102	$1,789
Other current liabilities	263	270
Total current liabilities	1,365	2,059
Common stock warrant and option liabilities	1,073	347
Total liabilities	2,438	2,406
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 2,056,884 and 1,373,120 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	66	65
Additional paid-in capital	288,421	285,292
Accumulated deficit	(285,602)	(281,217)
Total stockholders' equity	2,885	4,140
Total liabilities and stockholders’ equity	$5,323	$6,546

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.